MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 133 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q4 2023. The put-call ratio across all filers is 1.05 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $956,403,957 | -12.5% | 21,751,284 | 0.0% | 26.80% | -10.8% |
| Q1 2024 | $1,092,566,995 | -16.8% | 21,751,284 | 0.0% | 30.04% | -8.6% |
| Q4 2023 | $1,313,560,041 | +5.9% | 21,751,284 | 0.0% | 32.87% | -1.7% |
| Q3 2023 | $1,239,823,188 | +11.8% | 21,751,284 | 0.0% | 33.43% | +8.1% |
| Q2 2023 | $1,109,315,484 | +138.4% | 21,751,284 | 0.0% | 30.92% | +81.8% |
| Q1 2023 | $465,259,965 | +103.7% | 21,751,284 | 0.0% | 17.01% | +76.4% |
| Q4 2022 | $228,388,482 | +31.9% | 21,751,284 | 0.0% | 9.64% | +34.8% |
| Q3 2022 | $173,140,000 | +51.6% | 21,751,284 | 0.0% | 7.15% | +29.7% |
| Q2 2022 | $114,194,000 | – | 21,751,284 | – | 5.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $956,403,957 | 26.80% |
| Cormorant Asset Management, LP | 8,494,151 | $373,487,819 | 21.58% |
| Finepoint Capital LP | 388,835 | $17,097,075 | 4.85% |
| Ghost Tree Capital, LLC | 300,000 | $13,191,000 | 4.13% |
| 5AM Venture Management, LLC | 282,313 | $12,413,303 | 2.78% |
| Logos Global Management LP | 750,000 | $32,977,500 | 2.68% |
| MPM BioImpact LLC | 343,235 | $15,092,043 | 2.34% |
| Altium Capital Management LP | 115,000 | $5,056,550 | 2.06% |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 228,803 | $10,060,468 | 1.64% |
| Avoro Capital Advisors LLC | 2,770,000 | $121,796,900 | 1.62% |